|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Trade receivables, net of allowances | ||||||||||||||||||||
| Investment in marketable securities | ||||||||||||||||||||
| Amount due from sale of MST Franchise | ||||||||||||||||||||
| Prepaid and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Non-Current Assets: | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right of use assets (Note 9) | ||||||||||||||||||||
| Non-current prepaid expenses and other assets | ||||||||||||||||||||
| Total Non-Current Assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Trade payables | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Employee-related obligations | ||||||||||||||||||||
| Liability for employee severance benefits | ||||||||||||||||||||
| Operating lease liabilities (Note 9) | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Non-current operating lease liabilities (Note 9) | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Long-term Liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Convertible Preferred Stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2023 and December 31, 2022; Series A Preferred Stock: 0 and 3,000 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively (Note 12) | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock: $0.0001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025; and 668,327 and 666,463 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
Loading...
